Apimed
Old drugs for new medicines
- Home page /
- Our innovative offers /
- Therapeutic
Competitive advantages
- Time reduction to market a molecule
- Time reduction for clinical phase tests
- New antiparasitic molecules
The Toxoplasma model enables to analyze both parasitic and human cells. The use of different technologies and the expertise of our team produced a reliable process for drug discovering and target deconvolution. For clients, costs and timings will be reduced by a technology “ready to use”.
Market opportunities
- Drug repurposing
- Toxoplasma
- Target deconvolution
Development level
Although the POC is described in different scientific publications, the validation of the molecular screening and the target-deconvolution process is ongoing to patent new “drug-target” couples and consolidate the IP portfolio. Two public fellowships (ANR, FRM) support the project.
TRL4
Search for partnerships
Maturation (via SATT Linksium)
Intellectual property
-
Researcher / Laboratory
Mohamed-Ali HAKIMI / IAB
Presentation
Drug repurposing and target deconvolution strategies are currently used by pharmaceutical industries to accelerate the process of drug discovering and the time to market of a molecule. A problem which concerns every therapy and associated diseases.
The entire process is based on the Toxoplasma gondii parasite model. It includes a large phenotypic screening of molecules with antiparasitic activity, followed by genetic approaches, in vitro and in vivo drug-target interaction analyses, to identify the molecular target and the mechanism of action.
Uses
- Safety and efficiency tests on molecules before passing to the clinical phases
- Drug repositioning for zoonoses
- In vivo efficiency, toxicity and intestinal permeability tests
- Chemical modification of molecules to increase their safety and efficiency for the described inhibitory pathways
Contacts
7 Allée Palestine
38610 Gières
Tél : +33 (0)4 56 52 04 30
E-mail : contact@floralis.fr
